Bristol Makes Major Investment In Padlock's Autoimmune Platform
This article was originally published in The Pink Sheet Daily
Executive Summary
Pharma buys preclinical technology that may fight autoimmune disorders like rheumatoid arthritis with a new mechanism, blocking the creation of autoantigens that drive disease progression.